logo
  

WellPoint Q3 Adj. Profit Tops View - Quick Facts

Health insurer WellPoint, Inc. (WLP) said third-quarter net income was $630.9 million, down from $656.2 million in the comparable quarter last year. Earnings per share for the latest third quarter rose to $2.22 from $2.16 last year.

Excluding items, adjusted net income for the recent quarter rose to $671.7 million or $2.36 per share from $640.6 million or $2.10 per share in the prior year period. On average, 22 analysts polled by Thomson Reuters expected earnings per share of $2.27 for the quarter. Analysts' estimates typically exclude one-time items.

Quarterly total revenues reached $18.56 billion, a 3.9% increase, compared with the year-ago figure of $17.86 billion, with total operating revenue growing 4.3% year-over-year to $18.37 billion, from $17.62 billion. Sixteen analysts estimated $18.72 billion in revenues for the period.

For full year 2014, the company now expects net income to be within the range of $8.83 to $8.93 per share, including $0.08 per share of net favorable items in the first nine months. Excluding these items, adjusted net income is projected to be in the range of $8.75 to $8.85 per share. The company now expects operating revenue to be in the range of $73.25 billion to $73.5 billion.

Analysts now project annual earnings of $8.72 per share on revenues of $73.50 billion for 2014.

Earlier, the company expected net income to exceed $8.81 per share, including $0.21 per share of net favorable items in the first half. Excluding items, adjusted net income was projected to be greater than $8.60 per share. Annual operating revenue was expected to be more than $73.5 billion.

On October 28, 2014, the Audit Committee declared a fourth quarter 2014 dividend to shareholders of $0.4375 per share. The fourth quarter dividend is payable on December 22, 2014, to shareholders of record at the close of business on December 5, 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT